ArticleDigestive diseases and sciences2026
Screening of Avoidance/Restrictive Food Intake Disorder (ARFID) in Patients with Quiescent Inflammatory Bowel Disease and Irritable Bowel Syndrome-Like Symptoms.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEven in the absence of active inflammation, patients with inflammatory bowel diseases (IBD) frequently report symptoms consistent with irritable bowel syndrome (IBS), which may lead to restrictive dietary patterns and ultimately increase the risk of avoidant/restrictive food intake disorder (ARFID). The aim was to evaluate the prevalence of patients at risk of ARFID among individuals with quiescent IBD and IBS-type symptoms, and to evaluate its association with the FODMAP intake.
methodsA cross-sectional study was conducted on adult IBD patients followed in a tertiary Belgian center whose recent work-up showed endoscopic and biological remission as per STRIDE II criteria. Self-administered questionnaires (NIAS-Fr, SCOFF-F, FFQ-FODMAP-BE, GAD-7, PHQ-9, IBS SSS, PRO-2, HBI) were completed remotely via REDCap. Univariate and multivariate logistic regressions were performed, with the significant threshold fixed at 5%.
resultsSixty-two patients were enrolled (65% female, 66% Crohn's disease, mean age 39 ± 14 years). Overall, 16 patients (26%) were screened positive for ARFID risk. Among these 16 patients, the distribution across subscales (picky eater, small appetite, fear of eating) was as follows: 63% (10/16) fulfilled one subscale, 31% (5/16) fulfilled two subscales, 6% (1/16) fulfilled all three. Higher IBS symptom severity was associated with a higher risk of positive screening for ARFID. In a multivariate logistic regression model, positive screening for risk of ARFID was associated with mild FODMAP consumption (FFQ-FODMAP-BE < 1.80) and anxiety.
conclusionOne in four patients with quiescent IBD has a positive screening for ARFID. Anxiety and low FODMAP intakes are associated with positive screening.
Indexed as
Identifiers
42329518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.